

# Dyskinesia - Pipeline Review, H2 2020

<https://marketpublishers.com/r/DA5E756AD75EN.html>

Date: September 2020

Pages: 262

Price: US\$ 2,000.00 (Single User License)

ID: DA5E756AD75EN

## Abstracts

Dyskinesia - Pipeline Review, H2 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2020, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape.

Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chewing and tongue thrusting. The disease can be controlled by healthy life style and medication.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Dyskinesia - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Dyskinesia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dyskinesia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dyskinesia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 3, 14, 8, 1, 27 and 5 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules,

respectively.

Dyskinesia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## **SCOPE**

The pipeline guide provides a snapshot of the global therapeutic landscape of Dyskinesia (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Dyskinesia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Dyskinesia (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Dyskinesia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline

projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Dyskinesia (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Dyskinesia (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Dyskinesia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Dyskinesia - Overview

Dyskinesia - Therapeutics Development

Dyskinesia - Therapeutics Assessment

Dyskinesia - Companies Involved in Therapeutics Development

Dyskinesia - Drug Profiles

Dyskinesia - Dormant Projects

Dyskinesia - Discontinued Products

Dyskinesia - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Dyskinesia, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Products under Development by Companies, H2 2020  
Products under Development by Universities/Institutes, H2 2020  
Number of Products by Stage and Target, H2 2020  
Number of Products by Stage and Mechanism of Action, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Dyskinesia - Pipeline by Adamas Pharmaceuticals Inc, H2 2020  
Dyskinesia - Pipeline by Addex Therapeutics Ltd, H2 2020  
Dyskinesia - Pipeline by AEON Biopharma Inc, H2 2020  
Dyskinesia - Pipeline by Amarantus Bioscience Holdings Inc, H2 2020  
Dyskinesia - Pipeline by Astraea Therapeutics LLC, H2 2020  
Dyskinesia - Pipeline by Bod Australia Ltd, H2 2020  
Dyskinesia - Pipeline by Cadent Therapeutics Inc, H2 2020  
Dyskinesia - Pipeline by Cannabis Science Inc, H2 2020  
Dyskinesia - Pipeline by Cavion LLC, H2 2020  
Dyskinesia - Pipeline by Cerevance Inc, H2 2020  
Dyskinesia - Pipeline by Cerevel Therapeutics LLC, H2 2020  
Dyskinesia - Pipeline by Contera Pharma ApS, H2 2020  
Dyskinesia - Dormant Projects, H2 2020  
Dyskinesia - Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Dyskinesia, H2 2020  
Number of Products under Development by Companies, H2 2020  
Number of Products under Development by Universities/Institutes, H2 2020  
Number of Products by Top 10 Targets, H2 2020  
Number of Products by Stage and Top 10 Targets, H2 2020  
Number of Products by Top 10 Mechanism of Actions, H2 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020  
Number of Products by Routes of Administration, H2 2020  
Number of Products by Stage and Routes of Administration, H2 2020  
Number of Products by Molecule Types, H2 2020  
Number of Products by Stage and Molecule Types, H2 2020

### COMPANIES MENTIONED

Adamas Pharmaceuticals Inc  
Addex Therapeutics Ltd  
AEON Biopharma Inc  
Amarantus Bioscience Holdings Inc  
Astraea Therapeutics LLC  
Bod Australia Ltd  
Cadent Therapeutics Inc  
Cannabis Science Inc  
Cavion LLC  
Cerevance Inc  
Cerevel Therapeutics LLC  
Contera Pharma ApS  
DanPET AB  
Domain Therapeutics SA  
EpiVax Inc  
GW Pharmaceuticals Plc  
H. Lundbeck AS  
Hua Medicine Shanghai Ltd  
Ipsen SA  
IRLAB Therapeutics AB  
Jazz Pharmaceuticals Plc

Junaxo Inc  
Med-Life Discoveries LP  
Medytox Inc  
Melior Pharmaceuticals II LLC  
MitoDys Therapeutics Ltd  
Motac Neuroscience Ltd  
NeurAxon Pharma Inc  
Neurim Pharmaceuticals Ltd  
Neurocea Pharmaceuticals  
Neurocrine Biosciences Inc  
Neurolix Inc  
Newron Pharmaceuticals SpA  
Nissan Chemical Corp  
OB Pharmaceuticals  
Peptron Inc  
PolyCore Therapeutics LLC  
Praxis Precision Medicines Inc  
Prilenia Therapeutics Development Ltd  
Revance Therapeutics Inc  
Sage Therapeutics Inc  
SalubRx Therapeutics Inc  
Sinopia Biosciences Inc  
SOM Biotech SL  
Sosei Heptares  
Teva Pharmaceutical Industries Ltd  
Trevi Therapeutics Inc  
Ultragenyx Pharmaceutical Inc  
VistaGen Therapeutics Inc

## I would like to order

Product name: Dyskinesia - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/DA5E756AD75EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DA5E756AD75EN.html>